Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
Journal of Bone and Mineral Research, 02/22/2013Glüer CC et al.
Data on treatment of glucocorticoid–induced osteoporosis (GIO) in men are scarce. In this 18–month trial in men with GIO, teriparatide showed larger improvements in spinal BMD, microstructure, and finite element (FE)–derived strength than risedronate.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.